Cantor Fitzgerald analyst William Tanner reiterates an Overweight rating and $28 price target on shares of TherapeuticsMD following the company's Q4 results. The possibility of dual approvals could make for a "breakout year" in 2018, Tanner tells investors in a post-earnings research note. He believes TX-004 could become an important therapy with which to treat vulvar vaginal atrophy. Further, the "evolving regulatory landscape" for drug compounders should position TX-001 as an attractive alternative commercial product for compounding pharmacies, the analyst adds.